ReachMD

Joaquin Mateo received his MD from the University of Barcelona in 2006. After completing his medical training in Oncology at the Catalan Institute of Oncology (ICO, Barcelona), he completed postgraduate studies in clinical trial design, with a particular focus on early-phase clinical trials with companion biomarker development. He joined the Drug Development Unit at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (London) in 2011 for a two-year fellowship under the mentorship of Johann de Bono and Stan Kaye, working in first-in-man clinical trials of several PARP inhibitors and compounds targeting the PI3K-AKT-mTOR pathway. From 2013, he progressively focused his work towards the design and development of clinical trials for castration-resistant prostate cancer (CRPC). His main interest is the integration of tumour molecular characterisation data into real-time clinical decision-making for patients through multidisciplinary tumour boards, and was involved in the setting up of the molecular tumour boards at the Drug Development Unit and Prostate Cancer Targeted Therapy Unit, The Royal Marsden. After receiving a joint Medical Research Council & Prostate Cancer UK Fellowship award in 2014, he pursued a PhD at The Institute of Cancer Research (London); the focus of his research centered on achieving a better understand of the prevalence and clinical relevance of germline and somatic DNA repair defects in the progression of prostate cancer and how to therapeutically exploit these aberrations. In 2016, he received a Prostate Cancer Foundation Young Investigator Award to continue working on the development of PARP inhibitors, platinum-based therapies and companion predictive biomarkers for CRPC patients. Joaquin joined the Vall d´Hebron Institute of Oncology in November 2017 as Principal Investigator of its newly established Prostate Cancer Translational Research Group to lead research aimed at translating prostate cancer genotypes into phenotypes and a clinically relevant classification of the disease. He and his team will also seek to build a precision medicine core for prostate cancer patients.